Jiangsu Aidea Pharmaceutical Co., Ltd.

688488

CNE1000041S6

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
15.4 ^CNY	-1.09%		-5.29%	+23.10%

04-25	Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-23	Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Jiangsu Aidea Pharmaceutical Co., Ltd.(SHSE:688488) added to Shanghai Stock Exchange Composite Index

July 23, 2021 at 05:00 am

Jiangsu Aidea Pharmaceutical Co., Ltd.Has been added to Shanghai Stock Exchange Composite Index

Latest news about Jiangsu Aidea Pharmaceutical Co., Ltd.

Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Aidea Pharmaceutical, Subsidiaries Get Nod to Trial Anti-HIV Drug	01-09	MT
Aidea Pharmaceutical Unit Scraps Transfer Deal with Lixin Biotechnology for Anti-Tumor Drug	12-27	MT
Aidea Pharmaceutical's HIV Drug Granted Priority Review in China	11-21	MT
China's Drug Regulator Selects Aidea Pharmaceutical's HIV Drug for Priority Review	11-13	MT
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
Jiangsu Aidea Applies For 50 Million Yuan Bank Credit	01/09/23	MT
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	21/08/23	CI
Aidea Pharma to Apply For 50 Million Yuan Bank Loan	19/06/23	MT
Jiangsu Aidea Pharma to Apply For 60 Million Yuan Bank Loan	25/05/23	MT
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/04/23	CI
Jiangsu Aidea Pharma to Provide Services to China Medicines and Health Products in Three-Year Agreement	23/03/23	MT
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI
Jiangsu Aidea Pharma Sees Larger Loss in 2022	26/01/23	MT
Jiangsu Aidea Pharma Registers HIV Tablets	06/01/23	MT
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/08/22	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. agreed to acquire 19.9646% stake in Nanjing Nanda Pharmaceutical Co., Ltd. from Jiangsu Sheng Feng Medical Technology Company Limited for CNY 86 million.	18/07/22	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/04/22	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	25/02/22	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	27/10/21	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	26/08/21	CI
Jiangsu Aidea Pharmaceutical Co., Ltd.(SHSE:688488) added to Shanghai Stock Exchange A Share Index	23/07/21	CI
Jiangsu Aidea Pharmaceutical Co., Ltd.(SHSE:688488) added to Shanghai Stock Exchange Composite Index	23/07/21	CI

Chart Jiangsu Aidea Pharmaceutical Co., Ltd.

Duration

Period

Chart Jiangsu Aidea Pharmaceutical Co., Ltd.

More charts

Jiangsu Aidea Pharmaceutical Co Ltd is a China-based company mainly engaged in the production and sales of human-source protein products. The Company is also engaged in the development and sales of some generic drugs, human immunodeficiency virus (HIV) diagnostic equipment and reagents. The Company is also engaged in the research and development of innovative drugs in anti-Acquired Immune Deficiency Syndrome (AIDS), anti-inflammatory and anti-tumor drugs fields. The Company's human-source protein products mainly include crude ulinastatin, crude urekline, crude urokinase and intermediates of ulinastatin. The Company mainly distributes its products within domestic market.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.4

Average target price

Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
JIANGSU AIDEA PHARMACEUTICAL CO., LTD.	+23.10%	907M
CSL LIMITED	-2.32%	92.59B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.43B
BIOGEN INC.	-10.90%	33.49B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.62B
INCYTE CORPORATION	-9.06%	12.77B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.58B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.35B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.97B
INNOVENT BIOLOGICS, INC.	-6.32%	8.3B

Biopharmaceuticals